Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial

BACKGROUND: In the phase III AVAGAST trial, the addition of bevacizumab to chemotherapy improved progression-free survival (PFS) but not overall survival (OS) in patients with advanced gastric cancer. We studied the role of Angiopoietin-2 (Ang-2), a key driver of tumour angiogenesis, metastasis and...

Descripción completa

Detalles Bibliográficos
Autores principales: Hacker, Ulrich T, Escalona-Espinosa, Laura, Consalvo, Nicola, Goede, Valentin, Schiffmann, Lars, Scherer, Stefan J, Hedge, Priti, Van Cutsem, Eric, Coutelle, Oliver, Büning, Hildegard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984795/
https://www.ncbi.nlm.nih.gov/pubmed/27031850
http://dx.doi.org/10.1038/bjc.2016.30

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984795/
https://www.ncbi.nlm.nih.gov/pubmed/27031850
http://dx.doi.org/10.1038/bjc.2016.30

Ejemplares similares